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The lack of appropriate animal models has hampered efforts to develop therapies for Duchenne
muscular dystrophy (DMD). A new mouse model lacking both dystrophin and telomerase (Sacco
et al., 2010) closely mimics the pathological progression of human DMD and shows that muscle
stem cell activity is a key determinant of disease severity.Duchenne muscular dystrophy (DMD) is
among the most common inherited disor-
ders and is characterized by progressive
muscle wasting leading to loss of ambula-
tion and premature death. DMD and other
forms ofmuscular dystrophy are the focus
of intensive efforts to develop treatments,
as current interventions have only a minor
impact on disease progression. Testing of
experimental therapies has centered on
various strains of dystrophin mutant
(mdx) mice. Despite sharing the same
genetic defect as DMD patients (muta-
tions in the dystrophin gene), mdx mice
have a slowly progressive muscle
pathology, which except for the dia-
phragm muscle, does not lead to the
widespread formation of fibrous connec-
tive tissue and loss of muscle mass that
characterize the human disease. Unlike
DMD patients, mdx mutant mice do not
lose the ability to walk and display only
a 20% reduction in life span (Chamberlain
et al., 2007). Although studies of mdx
mutant mice have led to important
advances in our understanding of the
pathophysiology of dystrophy and have
allowed development of several prom-
ising approaches to therapy (Muir and
Chamberlain, 2009), the slowly progres-
sive phenotype has prompted efforts to
create an mdx model that more closely
resembles the human disorder. In this
issue of Cell, Sacco et al. (2010) report
a new mdx model that lacks telomerase
(mTR) activity and therefore shows
a reduction in the regenerative capacity
of myogenic stem cells. These mdx/mTR
double-knockout mice display a more
severe, rapidly progressing phenotype
and a greatly reduced life span. This new1040 Cell 143, December 23, 2010 ª2010 Elsstrain could enhance our understanding
of the mechanisms of disease progres-
sion in DMD while providing a new plat-
form for testing genetic, stem cell, and
pharmacologic approaches for treating
DMD.
Dystrophin, the protein product en-
coded by theDMD locus, links the internal
muscle cytoskeleton to the extracellular
matrix, enabling lateral transmission of
the forces of contraction from within
muscle cells to the surrounding matrix.
Loss of dystrophin renders multinucle-
ated skeletal muscle cells, known as
myofibers, susceptible to exercise-
induced injury. Injury results in necrosis
of segments of the myofiber, triggering
a cycle of degeneration and regeneration,
the latter of which is supported by
myogenic stem cells (Figure 1). Earlier
efforts to generate a mouse DMD model
with a more severe phenotype led to the
creation of a dystrophin:utrophin double-
knockout mouse. The severe pathology
in these mice results from the loss of
expression of the dystrophin paralog utro-
phin, which can compensate for the lack
of dystrophin in muscle (Deconinck
et al., 1997). However, DMD patient
muscles do express utrophin, and as
such, this mouse model does not fully
mimic the human disorder. In the past
year, an mdx double-mutant mouse
involving cytidine monophosphate-sialic
acid hydroxylase (Cmah) was generated
that appears to more closely resemble
the human DMD pathophysiology at
both a phenotypic and molecular level.
The Cmah/mdx double-knockout mouse
carries a human-specific mutation that
prevents protein glycosylation withevier Inc.N-glycolylneuraminic acid (Neu5Gc),
leading to a more severe phenotype and
shortened life span (Chandrasekharan
et al., 2010). It is unclear how the inability
of cells to incorporate the sialic acid
Neu5Gc onto glycoproteins and glyco-
lipids leads to a more severe dystrophy,
but this change presumably alters the
integrity of myofiber plasma membranes
(the sarcolemma) (Figure 1). Sacco et al.
now create an mdx/mTR double mutant
to test the hypothesis that murine
muscles have increased regenerative
capacity relative to human muscles due
to the longer telomeres found in mouse
relative to human myogenic stem cells
(Figure 1). Thus, a greater regenerative
capacity in mouse muscles may
contribute to the relatively mild phenotype
of mdx mutant mice.
The longer telomeres in murine somatic
cells relative to humans greatly reduce
their propensity to undergo replicative
senescence, i.e., lose the ability to enter
mitosis (Blasco et al., 1997; Kipling and
Cooke, 1990). Previous studies have also
shown that lossof telomerase, theenzyme
that extends telomeres, can accelerate
a number of pathophysiological changes
associated with aging in mice (Rudolph
et al., 1999). However, telomerase-defi-
cient mice do not show abnormalities of
muscle, probably due to the stable post-
mitotic nature of this tissue. By crossing
a telomerasemutation onto thedystrophic
mdx background, Sacco et al. create
a situation in which myogenic stem cells
carrying shortened telomeres (due to
loss of telomerase) are forced into active
and continuous proliferation to counter
the ongoing cycles of myofiber necrosis
Figure 1. New Model for Duchenne Muscular Dystrophy
(A) Sacco et al. (2010) generate a newmouse model for DMD by crossing dys-
trophin-deficientmdxmice (the current DMDmodel) withmice carrying amuta-
tion in the telomerase gene (mTRHETmice). Inbreeding of the resulting hetero-
zygotes (mdx/mTRHET) produces double-knockout mice (mdx/mTRKO) that
show decreasing telomere length (T) in the first and second generations and
a corresponding decrease in the capacity of myogenic stem cells (satellite
cells) to proliferate. These mice display a rapidly progressing muscular
dystrophy phenotype that more closely mimics the human disease compared
to the current model. Note that mdx is an X-linked gene. For simplicity, the
complete mdx genotype is not depicted in the figure.
(B) Dystrophic muscles are highly susceptible to contraction-induced injury,
which impairs the protective sheath around myofibers (the sarcolemma),
leading to myofiber necrosis and activation of nearby satellite cells. Activated
satellite cells divide asymmetrically, giving rise to one satellite cell and a prolif-
erating daughter cell that generates myoblasts. The myoblasts migrate to the
site of injury, differentiate into myocytes, align, and fuse into the damagedmy-
ofiber, repairing the lesion.and regeneration (due to loss
of dystrophin) (Figure 1).
These mutations may there-
fore create conditions in
mice that mimic the human
DMD phenotype.
Muscle regeneration re-
quires the activation and
proliferation of resident stem
cells known as satellite cells
(Collins et al., 2005). Sacco
et al. demonstrate a marked
decrease in the ability of acti-
vated satellite cells frommdx/
mTR mice to proliferate and
support regeneration in vitro,
in vivo in dystrophic mdx/
mTR muscles, or when trans-
planted into wild-type or
dystrophic muscles. With
their reduced regenerative
capacity, these double-
mutant mouse satellite cells
more closely resemble
human DMD satellite cells,
and as a result, the mdx/
mTRmice display an acceler-
ated onset and progression of
the dystrophic phenotype
more akin to the human
disease. The disease model
created by Sacco et al. thus
suggests that reduced regen-
erative capacity in humans
(relative to mice) may explain
at least some of the differ-
ences in the severity of
disease caused by dystro-
phin mutations. Replicative
senescence is usually ob-
served in mitotically active
cells derived from elderly indi-
viduals, and as such, DMD
has characteristics of a
premature aging syndrome
given that the myogenic
stem cells become prema-
turely senescent. The mdx/
mTR double-mutant muscle
phenotype underscores the
tremendous requirement for
continuous myogenic stem
cell proliferation needed to
support dystrophic muscle
regeneration. This ongoing,
lifelong myogenic stem cell
proliferation may also con-
tribute to the acquisitionCell 143, December 23,of mutations that lead to
a high frequency of rhabdo-
myosarcoma tumors in
muscles of old mdx mice
(Chamberlain et al., 2007).
What is the immediate
utility of the new mouse
model for DMD? One is
the potential to gain new
insights into mechanisms of
dystrophic progression that
take into account limitations
on muscle regenerative
capacity. A second is to rein-
force the concept that DMD
arises not just from intrinsic
defects in muscle function,
but also from a progressive
loss of regenerative capacity
due to the continuous prolif-
eration requirements placed
on myogenic stem cells in
a dystrophic environment.
Thus, an effective therapy for
DMD will need to not only
restore function to mature
myofibers, but also to halt or
greatly slow ongoing myo-
fiber necrosis to minimize
the recruitment of satellite
cells in order to avoid acquisi-
tion of replicative senes-
cence. This study may also
spur creative approaches to
overcome limitations inherent
to stem cell transplantation
therapies due to the limited
proliferative capacity of adult
somatic stem cells. New
stem cell therapies for
muscular dystrophies will
need to take into account
the replicative life span of
donor cells and may benefit
from the use of myogenic
progenitors derived from
induced pluripotent stem
cells, which maintain normal
telomere lengths (Takahashi
and Yamanaka, 2006).
Even if the new variants of
mdx mutant mice do not
spur the development of new
therapies for muscular
dystrophies, they are likely to
prove valuable. The mdx/
mTR double-mutant mice
increase the power of2010 ª2010 Elsevier Inc. 1041
therapeutic testing by providing greater
resolution between normal and dystro-
phic muscle function (Sacco et al., 2010;
Chandrasekharan et al., 2010). For
example, a variety of structurally distinct
microdystrophins (miniaturized versions
of dystrophin that can be efficiently deliv-
ered to dystrophic muscles using ad-
enoassociated viral vectors) are being
tested for use in gene therapy for DMD
(Muir and Chamberlain, 2009). However,
it can be challenging to identify the
constructs that work best in ameliorating
the relatively mild pathophysiology of
mousemdxmutantmuscles. The stronger
phenotype of the mdx/mTR double-
mutant mice provides a better back-
ground for testing therapies. This issue
is significant because even subtle func-
tional changes in mdx muscle function
could translate into significant quality of
life issues for patients. Similar arguments
can be made for testing almost all types
of experimental DMD therapies.
One limitation of the new mdx/mTR
mouse model is the somewhat elaborate1042 Cell 143, December 23, 2010 ª2010 Elsbreeding scheme required to achieve the
desired genotype. Given the significant
therapeutic advances achieved using the
currentmdxmodels, it should be possible
to perform initial or routine testing in the
standard mdx strains and use the more
severely affected double-mutant strains
for secondary and follow-up testing.
Nevertheless, the increased power of
analysis afforded by the newer mutations
may reduce the number of large animal
model studies needed for preclinical
testing of DMD therapeutics and thereby
accelerate thedevelopment of a treatment
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Two papers in this issue of Cell (Paradis-Bleau et al., 2010 and Typas et al., 2010) report that the
lipoproteins LpoA and LpoB are required for the synthesis of cell walls in Escherichia coli. Attached
to the bacterial outer membrane, these new cell wall components regulate penicillin-binding
proteins located at the inner membrane.Cell walls protect bacteria against osmotic
lysis. In Gram-negative bacteria, this en-
closingenvelopeconsistsof acytoplasmic
membrane surrounded by an outer
membrane. Sandwiched between the
twomembranes is thepeptidoglycanpoly-
mer, the rigid scaffolding that gives the
wall its strength. Peptidoglycan consistsof repeating linear polymers of N-acetyl-
glucosamine and N-acetylmuramic acid
linked together via short oligopeptide
chains. Because the enzymes that synthe-
size peptidoglycan are the targets of one
of the most important classes of antibi-
otics, the b-lactams, there is great interest
in understanding their activities and regu-lation. In this issue of Cell, two groups
(Paradis-Bleau et al., 2010; Typas et al.,
2010) identify new components of the cell
wall synthetic machinery in E. coli, adding
unexpected complexity to a process that
we thought we understood fairly well.
The final stage of peptidoglycan
synthesis depends on the high molecular
